Roche Acquires Diabetes Biotech Marcadia
This article was originally published in The Pink Sheet Daily
Executive Summary
In the wake of its taspoglutide disappointment, Roche is acquiring privately-owned U.S. metabolic treatment maker Marcadia Biotech for an undisclosed sum.
You may also be interested in...
Boehringer Enhances Diabetes Pipeline With Zealand's GLP-1/Glucagon Agonist
Boehringer wins global rights to Zealand's Phase I-ready novel diabetes compound, pledging €20 million during 2011.
Boehringer Enhances Diabetes Pipeline With Zealand's GLP-1/Glucagon Agonist
Boehringer wins global rights to Zealand's Phase I-ready novel diabetes compound, pledging €20 million during 2011.
Translational R&D Models Like Precompetitive Alliances Needed To Energize Drug Discovery - Indian Symposium
AHMEDABAD, India - Precompetitive collaborations between pharmaceutical companies mainly aimed at identifying biomarkers should intensify further to help weed out undesirable molecules in trials sooner than in expensive Phase II or III studies. Industry-academia alliances are increasingly gravitating in the same direction